blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2611439

EP2611439 - COMPOSITION COMPRISING A COMBINATION OF DHA AND EPA FOR PARENTERAL ADMINISTRATION PRIOR TO COMMENCEMENT OF CHEMOTHERAPY [Right-click to bookmark this link]
Former [2013/28]COMPOSITION COMPRISING A COMBINATION OF DHA AND EPA FOR ADMINISTRATION PRIOR TO COMMENCEMENT OF CHEMOTHERAPY
[2017/36]
StatusOpposition rejected
Status updated on  01.12.2023
Database last updated on 11.04.2026
FormerThe patent has been granted
Status updated on  19.01.2018
FormerGrant of patent is intended
Status updated on  31.08.2017
FormerExamination is in progress
Status updated on  24.03.2017
Most recent event   Tooltip01.12.2023Opposition rejectedpublished on 03.01.2024  [2024/01]
Applicant(s)For all designated states
Fresenius Kabi Deutschland GmbH
Else-Kröner-Strasse 1
61352 Bad Homburg v.d.H. / DE
[2013/28]
Inventor(s)01 / SCHLOTZER, Ewald
Fasanenweg 13
61440 Oberursel / DE
02 / KRAMPITZ, Barbara
Hamburger Allee 50
60486 Frankfurt am Main / DE
03 / SUCHNER, Ulrich
Waldstr. 27
85435 Erding / DE
 [2013/28]
Representative(s)Fresenius Kabi Deutschland GmbH
Patent Department
Pharmaceuticals Division
Borkenberg 14
61440 Oberursel / DE
[N/P]
Former [2018/08]Fresenius Kabi Deutschland GmbH
Patent Department
Else-Kröner-Straße 1
61352 Bad Homburg / DE
Former [2013/28]Fresenius Kabi Deutschland GmbH
Patent Department Else-Kröner-Straße 1
61352 Bad Homburg / DE
Application number, filing date11746585.626.08.2011
[2018/08]
WO2011EP64693
Priority number, dateUS20100379775P03.09.2010         Original published format: US 379775 P
EP2010017529303.09.2010         Original published format: EP 10175293
[2013/28]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2012028543
Date:08.03.2012
Language:DE
[2012/10]
Type: A1 Application with search report 
No.:EP2611439
Date:10.07.2013
Language:DE
The application published by WIPO in one of the EPO official languages on 08.03.2012 takes the place of the publication of the European patent application.
[2013/28]
Type: B1 Patent specification 
No.:EP2611439
Date:21.02.2018
Language:DE
[2018/08]
Search report(s)International search report - published on:EP08.03.2012
ClassificationIPC:A61K31/202, A61K31/513, A61P43/00, A61N5/10
[2017/36]
CPC:
A61K31/202 (EP,US); A61K31/513 (EP,US); A61N5/10 (US);
A61N5/1001 (US); A61P39/00 (EP); A61K35/60 (EP)
C-Set:
A61K31/202, A61K2300/00 (EP,US)
Former IPC [2013/28]A61K31/202, A61K45/06, A61P43/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/28]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:DIE PARENTERALE APPLIKATION VON FISCHÖL/DHA +EPA VOR BZW. MIT BEGINN DER CHEMOTHERAPIE[2017/36]
English:COMPOSITION COMPRISING A COMBINATION OF DHA AND EPA FOR PARENTERAL ADMINISTRATION PRIOR TO COMMENCEMENT OF CHEMOTHERAPY[2017/36]
French:COMPOSITION COMPRENANT UNE COMBINAISON DE DHA ET D'EPA À ADMINISTRER PAR VOIE PARENTÉRALE AVANT LE DÉBUT D'UNE CHIMIOTHÉRAPIE[2017/36]
Former [2013/28]ZUSAMMENSETZUNG UMFASSEND EINE KOMBINATION VON DHA UND EPA ZUR GABE VOR BEGINN DER CHEMOTHERAPIE
Former [2013/28]COMPOSITION COMPRISING A COMBINATION OF DHA AND EPA FOR ADMINISTRATION PRIOR TO COMMENCEMENT OF CHEMOTHERAPY
Former [2013/28]COMPOSITION COMPRENANT UNE COMBINAISON DE DHA ET D'EPA À ADMINISTRER AVANT LE DÉBUT D'UNE CHIMIOTHÉRAPIE
Entry into regional phase28.02.2013National basic fee paid 
28.02.2013Designation fee(s) paid 
28.02.2013Examination fee paid 
Examination procedure19.03.2012Request for preliminary examination filed
International Preliminary Examining Authority: EP
28.02.2013Examination requested  [2013/28]
09.10.2013Amendment by applicant (claims and/or description)
27.03.2017Despatch of a communication from the examining division (Time limit: M04)
20.07.2017Reply to a communication from the examining division
01.09.2017Communication of intention to grant the patent
10.01.2018Fee for grant paid
10.01.2018Fee for publishing/printing paid
10.01.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  27.03.2017
Opposition(s)Opponent(s)01  21.11.2018  26.11.2018  ADMISSIBLE
B. Braun Melsungen AG
Carl-Braun-Str.1
34212 Melsungen / DE
Opponent's representative
Prüfer & Partner mbB Patentanwälte · Rechtsanwälte
Sohnckestraße 12
81479 München / DE
 [2020/50]
Former [2018/52]
Opponent(s)01  21.11.2018    ADMISSIBLE
B. Braun Melsungen AG
Carl-Braun-Str.1
34212 Melsungen / DE
Opponent's representative
dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB
Deichmannhaus am Dom
Bahnhofsvorplatz 1
50667 Köln / DE
03.12.2018Invitation to proprietor to file observations on the notice of opposition
04.04.2019Reply of patent proprietor to notice(s) of opposition
20.01.2020Date of oral proceedings
12.02.2020Despatch of minutes of oral proceedings
12.02.2020Date of despatch of rejection of opposition
05.05.2023Legal effect of rejection of opposition [2024/01]
Appeal following opposition11.03.2020Appeal received No.  T0694/20
28.05.2020Statement of grounds filed
05.05.2023Result of appeal procedure: appeal of the opponent was rejected
29.11.2023Despatch of the decision of the Board of Appeal
05.05.2023Date of oral proceedings
Fees paidRenewal fee
29.08.2013Renewal fee patent year 03
22.08.2014Renewal fee patent year 04
19.08.2015Renewal fee patent year 05
10.08.2016Renewal fee patent year 06
13.07.2017Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU26.08.2011
CY21.02.2018
EE21.02.2018
RO21.02.2018
RS21.02.2018
SI21.02.2018
SK21.02.2018
SM21.02.2018
BG21.05.2018
GR22.05.2018
IS21.06.2018
[2020/33]
Former [2020/28]HU26.08.2011
CY21.02.2018
EE21.02.2018
RO21.02.2018
RS21.02.2018
SI21.02.2018
SK21.02.2018
SM21.02.2018
BG21.05.2018
GR22.05.2018
Former [2020/05]CY21.02.2018
EE21.02.2018
RO21.02.2018
RS21.02.2018
SI21.02.2018
SK21.02.2018
SM21.02.2018
BG21.05.2018
GR22.05.2018
Former [2019/13]CY21.02.2018
EE21.02.2018
MT21.02.2018
RO21.02.2018
RS21.02.2018
SI21.02.2018
SK21.02.2018
SM21.02.2018
BG21.05.2018
GR22.05.2018
Former [2018/52]CY21.02.2018
EE21.02.2018
MT21.02.2018
RO21.02.2018
RS21.02.2018
SK21.02.2018
SM21.02.2018
BG21.05.2018
GR22.05.2018
Former [2018/50]CY21.02.2018
EE21.02.2018
MT21.02.2018
RO21.02.2018
RS21.02.2018
SK21.02.2018
BG21.05.2018
GR22.05.2018
Former [2018/43]CY21.02.2018
MT21.02.2018
RS21.02.2018
BG21.05.2018
GR22.05.2018
Former [2018/40]CY21.02.2018
RS21.02.2018
BG21.05.2018
GR22.05.2018
Former [2018/37]CY21.02.2018
GR22.05.2018
Cited inInternational search[XI] WO9809621  (SCOTIA HOLDINGS PLC et al.) [X] 1-4 * claims 1,2 * * page 4 * * page 4, lines 2-5 * * page 3, lines 18-24 * * page 5, lines 24-28 * * page 5, lines 1-23 *[I] 5-14
 [XI] US2003068385  (MOYER MARY PAT et al.) [X] 1-4,7-11,13 * claims 1, 5, 8 *[I] 5,6,12,14
 [I] WO0149284  (EFA SCIENCES LLC et al.) [I] 1-14 * abstract *
 [I]   TAKAGI K ET AL: "Perioperative supplementation of EPA reduces immunosuppression induced by postoperative chemoradiation therapy in patients with esophageal cancer.", NUTRITION (BURBANK, LOS ANGELES COUNTY, CALIF.), vol. 17, no. 6, June 2001 (2001-06-01), pages 478 - 479, XP002614617, ISSN: 0899-9007 [I] 1-14 * abstract * * Patients and Methods; page 478, column r *

DOI:   http://dx.doi.org/10.1016/S0899-9007(01)00557-3
 [I]   ROTE LIST SERVICE: "Omegaven Fresenius", April 2010 (2010-04-01), XP002664639, Retrieved from the Internet [retrieved on 20111130] [I] 1-14 * the whole document *
by applicant  JEMAL ET AL., CA CANCER J CLIN, vol. 59, no. 4, 2009, pages 225 - 49 [I] 5-14
   LADEWSKI ET AL., J CLIN ONCOL., vol. 21, no. 20, 2003, pages 3859 - 66 [I] 5,6,12,14
OppositionUS2003068385
 WO9809621
   DRISCOLL, D.: "Lipid Injectable Emulsions: Pharmacopeial and Safety Is- sues", PHARMACEUTICAL RESEARCH, vol. 23, no. 9, 2006, pages 1959 - 1969, XP055534581
   DRISCOLL ET AL.: "Physicochemical stability of total nutrient admixtures", AM 3 HEALTH-SYST PHARM., vol. 52, 1995, pages 623 - 634, XP055534586

DOI:   http://dx.doi.org/10.1093/ajhp/52.6.623
   SANGEETHA SAGAR ET AL.: "Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells: relationship to free radicals and lipid pe- roxidation and its modulation by calmodulin antagonists", CANCER LETTERS, vol. 63, 1992, pages 189 - 198, XP055534590

DOI:   http://dx.doi.org/10.1016/0304-3835(92)90260-3
   CNOP ET AL.: "Troglitazone does not protect rat pancreatic beta cells against free fatty acid-induced cytotoxicity", BIOCHEMICAL PHARMACOLOGY, vol. 63, 2002, pages 1281 - 1285, XP055534598
   SIDDIQUI ET AL.: "Prevention of docosahexaenoic acid-induced cytotoxicity by phosphatidic acid in Jurkat leukemic cells: the role of protein phosphatase-1", BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1541, 2001, pages 188 - 200, XP055534601

DOI:   http://dx.doi.org/10.1016/S0167-4889(01)00143-4
   LISTENBERGER ET AL.: "Triglyceride accumulation protects against fatty acid-induced lipotoxicity", PNAS, vol. 100, no. 6, 2003, pages 3077 - 3082, XP055534603
   CNOP ET AL.: "Inverse Relationship Between Cytotoxicity of Free Fatty Acids in Pancreatic Islet Cells and Cellular Triglyceride Accumulation", DIABETES, vol. 50, 2001, pages 1771 - 1777, XP055534608

DOI:   http://dx.doi.org/10.2337/diabetes.50.8.1771
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.